abstract |
The present invention relates to the use of a GPR4 inhibitor in the manufacture of a medicament for inhibiting angiogenesis, for example inhibiting tumor growth in cancer therapy. In a preferred embodiment, the inhibitor is preferably a double stranded siRNA. In addition, the present invention further screens non-human animals in which GPR4 is inactivated, such as knockout mice lacking GPR4, and experimental models for angiogenesis, and compounds that modulate angiogenesis. Of the above animal uses. |